bluebird bio, Inc. BLUE
At closeJun 2, 2025, 4:00 PM EDT
52-week range unavailable
- YTD
- -40.41%
- 1 year
- -72.25%
- Market cap
- 75.74M
- Revenue (ttm)
- 54.90M
- Shares out
- 9.72M
- Forward P/E
- -11.98
- YTD return
- -40.41%
- 1-year return
- -72.25%
- Volume
- 1.25M
- Open
- 4.97
- Previous close
- 4.97
- Day's range
- 4.97 – 4.97
- Beta
- 0.80
- Analysts
- Hold
- Price target
- 37.71 (+658.8%)
2Y -3.82 (-43.46%)
Key statistics
- Enterprise value
- 321.89M
- PEG ratio
- 0.00
- Price / sales
- 1.38
- Price / book
- 7.72
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 133.70%
- Free cash flow
- -163.92M
- Total cash
- 144.07M
- Total debt
- 395.64M
- Return on equity
- -186.70%
- Short % of float
- 26.66%
- 50-day average
- 8.54
- 200-day average
- 16.13
Analyst view
Consensus: hold
- Target (low)
- 10.00
- Target (mean)
- 37.71
- Target (high)
- 80.00
- Strong buy1
- Buy1
- Hold6
- Sell0
- Strong sell2
Next earnings
Consensus EPS estimate -5.75.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -7.60 | -6.20 | +1.40 | +18.42% |
| Sep 13, 2024 | Dec 1, 2023 | 0.00 | -15.60 | — | — |
| Nov 7, 2023 | Sep 1, 2023 | -13.80 | -13.20 | +0.60 | +4.35% |
| Aug 8, 2023 | Jun 1, 2023 | -14.40 | -13.40 | +1.00 | +6.94% |
| May 9, 2023 | Mar 1, 2023 | -10.80 | 4.20 | +15.00 | +138.89% |
| Mar 29, 2023 | Dec 1, 2022 | -9.00 | 7.60 | +16.60 | +184.44% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | RBC Capital | reit | Sector Perform | Sector Perform |
| Nov 15, 2024 | B of A Securities | down | Buy | Neutral |
| Nov 15, 2024 | Barclays | main | Overweight | Overweight |
| Sep 25, 2024 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Sep 16, 2024 | Cantor Fitzgerald | reit | — | Neutral |
| Aug 15, 2024 | B of A Securities | main | Buy | Buy |
About bluebird bio, Inc.
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- bluebirdbio.com
News
Deal Dispatch: US M&A Is Quiet, But Abroad? Volume Is Spiking 
12 Health Care Stocks Moving In Friday's After-Market Session 
Earnings Scheduled For November 14, 2024 
This Snowflake Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday 
Earnings Scheduled For March 26, 2024 
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session 
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Your note
Sign in to keep a note on BLUE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AGWUNOBI JOHN O | Director | Stock Award(Grant) | Nov 5, 2024 | 51,364 |
| COLVIN RICHARD A | Officer | Sale | Dec 9, 2024 | 165,544 |
| JONES-BURTON CHARLOTTE M.D. | Director | Stock Award(Grant) | Nov 5, 2024 | 43,462 |
| LEIDERMAN ELISABETH M.D. | Director | Stock Award(Grant) | Nov 5, 2024 | 47,156 |
| LESCHLY NICK | Director | Stock Award(Grant) | Nov 5, 2024 | 484,538 |
| OBENSHAIN ANDREW | Chief Executive Officer | Sale | Dec 9, 2024 | 374,247 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 0.40% | 772,190 | 6.02M | Sep 29, 2024 |
| Vanguard Group Inc | 0.27% | 523,700 | 4.08M | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.12% | 234,152 | 1.82M | Sep 29, 2024 |
| State Street Corporation | 0.10% | 192,096 | 1.50M | Sep 29, 2024 |
| FMR, LLC | 0.06% | 124,098 | 966.72K | Sep 29, 2024 |
| Avidity Partners Management, LP | 0.04% | 81,557 | 635.33K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.15% | 293,123 | 2.28M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 0.13% | 250,270 | 1.95M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.08% | 159,570 | 1.24M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.05% | 98,622 | 768.26K | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.05% | 92,047 | 717.05K | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.03% | 54,344 | 423.34K | Oct 30, 2024 |